Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial.

已完结 20 由 ! 发布于 2025/7/13 16:23:45

DOI:10.1001/jamaoncol.2025.1694
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1001/jamaoncol.2025.1694

其它数据库

Abstract：Importance Patients with ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer (MBC) and brain metastases have poor prognosis, and effective treatment options are limited.

应助信息

1天前

冰敦敦儿

fd1c327c5fcc11f0be4234735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2025/7/13 16:23:45 未找到该文献，机器人已退出，请等待人工下载

2025/7/13 16:23:45 Book学术AI机器人收到请求，开始寻找文献

2025/7/13 16:23:45 已向机器人发送请求

1天前

! 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerDeep learning on routine full-breast mammograms enhances lymph node metastasis prediction in early breast cancer